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ROBLEMS caused by the use of psychoactive drugs touch
all areas of medicine and health care. Some problems are
well known and highly visible such as the respiratory ill-
nesses caused by smoking, liver disease from harmful alcohol con-
sumption and overdose from heroin injection. Others are more
subtle and often missed by health professionals as an underlying
cause of a wide range of health and social harms.
Personal and social problems from drug use are substantial and
cut across all domains of functioning including personal relation-
ships, family life, employment and psychological health.
The health and economic costs associated with the use of drugs
are high, with costs of legal drugs estimated to be substantially
higher than those from illegal drugs. The annual cost of drug use
in Australia is estimated to be $34.4 billion (Collins & Lapsley, 2002)
of which:
 $21.1 billion was from tobacco
 $7.6 billion from alcohol
 $6.1 billion from illicit drugs
The Australian Institute of Health and Welfare estimated that in
1998 there were 23,313 drug-related deaths in Australia of which
19,019 were due to smoking tobacco, 3,271 to risky alcohol use
and 1,023 to illicit drug use (Ridolfo & Stevenson, 2001). The bulk
of the latter comprised deaths from heroin overdose.
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In addit ion to drug-related deaths, in
1997–1998 there were:
 142,525 hospital separations attributable
to tobacco smoking
 71,422 attributable to risky alcohol use
 14,471 to illicit drugs
There are three main patterns of risky drug
use with corresponding patterns of problems.
These are:
 intoxication (e.g. violence, falls, road
trauma, overdose)
 regular use (e.g. liver disease, cancer)
 dependence (e.g. withdrawal symptoms,
social problems)
These three distinct patterns of use can oc-
cur within the one person, or in different
individuals.
There are also growing problems associated
with injecting drug use including the spread
of blood borne viruses. While the rate of HIV
infection amongst Australian injecting drug
users is still very low by world standards
(1–2%), hepatitis C is an emerging concern
and is likely to generate some thousands of
cases of liver disease in future years
(NCHECR, 1999).
TYPES OF DRUGS AND
THEIR EFFECTS
Identifying Harms
Alcohol- and drug-related harms are not spe-
cific to the effects of the drug. Harms result
from the interaction between:
The drug
 patterns of use (how much, when used,
how often)
 and other drugs used
The individual
 age, weight, gender and general health
 tolerance and previous experience of the
substance including intoxication, after ef-
fects and withdrawal
 expectations of use and effects
 current mood and psychological health
The environment
Factors that influence the drug’s effects and
patterns of use such as:
 social settings and company
 context of use
 patterns of drug use according to ritual or
culture
DRUG USAGE
Knowledge and understanding about pat-
terns and correlates of drug use are derived
from various sources including surveys.  Sur-
veys of drug use are usually (1) conservative
estimates of prevalence and (2) do not give
an indication of the number of people using
drugs in problematic ways. In the clinical set-
ting careful, individualised assessment is re-
quired to determine patterns and levels of
use.  The following provides brief highlights
of key drug use patterns (see relevant chap-
ters for more detail on specific drugs).
I
R
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Alcohol
Most Australians drink alcohol – 80% of Aus-
tralians aged 15 and over report drinking al-
cohol in the past year. The National Health
and Medical Research Council’s (NHMRC)
new Alcohol Guidelines (NHMRC, 2001) de-
fine low risk regular use as no more than 4
standard drinks per day for men and 2 for
women, and no more than 6 and 4 drinks for
males and females respectively on occasion.
A higher level of intake is now considered to
be low risk on an occasional basis, ie no more
than 6 standard drinks for men and 4 for
women, provided certain precautions and re-
strictions are observed (e.g. drinking less if at
all, when pregnant, not drinking before driv-
ing). However, there are many drinkers who
exceed these limits and 46% of males and
32% of females do so at least once a month
(Heale et al., 2000). Heavier patterns of con-
sumption are a concern for all health profes-
sionals as they are strongly associated with
a wide range of acute and chronic harms.
Tobacco
The 2001 National Drug Strategy Household
Survey found that 21% of males and 18% of
females smoked daily (AIHW, 2002).
Tobacco use amongst Indigenous Austral-
ians is 2 to 3 times higher than the broader
community.
Very few people smoke only occasionally and
there is no established safe level of tobacco
use. Early uptake of tobacco smoking by
young people is of concern for several rea-
sons including its highly addictive nature.
Other Drugs
Cannabis is the most widely used illicit drug
in Australia with 13% of all individuals aged
14 or over having used it during the previous
12 months (AIHW, 2002) and 33% at some
time in their lives.
Amphetamine and ecstasy use has become
increasingly prevalent: one in nine males aged
20–29 years reported using amphetamines in
the last 12 months. Males are generally more
likely to use, with the exception of teenagers
where use by girls is more prevalent than by
boys (AIHW, 2002).
Lifetime use of heroin is estimated to be 2%
and of cocaine 3–4% of the population. It is
estimated that in the year 2000 there were
approximately 74,000 dependent heroin us-
ers or 0.7% of Australians aged 15 to 54 years
of age (Hall et al., 2000).
Polydrug Use
Until recently it was common to characterise
illicit drug use by the drug, or class of drug,
primarily used. For instance, heroin users were
identified as a distinct category of user, as
were stimulant users. These characterisations
are no longer valid. Most illicit drug users are
likely to use a variety of substances. Drug
substitution also occurs. When there is a short-
age of some drugs (e.g. heroin) other drugs
(e.g. amphetamines, alcohol) may be used as
an alternative. Increased ease of availability
of drugs is likely to have contributed to diver-
sity in patterns of use.
See Chapter 4
Tobacco
See Chapters 5–12
See Chapter 3
Alcohol
www.nhmrc.gov.au/
publications/pdf/ds9.pdf
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* Note that the term ‘speedball’ some-
times also refers to a combination of
heroin and amphetamine.
Certain associations are well recognised;
for example:
 cigarettes and alcohol often go hand
in hand, particularly where heavy use
of either substance is involved
 cannabis smokers are almost invariably
tobacco smokers (although obviously the
reverse is not the case)
 heroin users often also take drugs such as
cocaine and benzodiazepines, and nearly
all heroin users are also cigarette smokers
 heavy drinkers also often use illicit drugs
Many illicit drug users possess sophisticated
pharmacological knowledge. Users often ex-
hibit considerable skill in the titration of vari-
ous substances when used in concert with one
another. For example, combinations of drugs
such as heroin and cocaine (known as
‘speedballs’ *) allow the sedative action of one
drug (i.e. the heroin) to take the sharp edge
off the stimulant (i.e. the cocaine). Similarly,
some substances are less commonly taken
when using another preferred drug e.g. some
users avoid taking ecstasy and alcohol con-
currently.
Multiple substance use complicates the as-
sessment process. Signs and symptoms of
intoxication for various drugs can be similar.
Also concurrent use can complicate with-
drawal. Polydrug use also confounds our un-
derstanding of dependence problems
(Gossop, 2001). A person who uses a range
of different psychoactive substances may not
be dependent on all drugs that he/she uses.
Comprehensive drug use histories are re-
quired, and no assumptions should be made
about patterns of use or non-use. It is impor-
tant to note that most available assessment
tools assess dependence (and not usually
problematic use) and for a single drug only,
or provide separate substance specific meas-
ures. Careful decisions regarding prioritisation
for treatment are needed. This should be done
in consultation with the client/patient.
Routes of Administration
Drugs can be taken in various ways. The
mode of administration is a significant medi-
ating factor on the effect of a drug. Various
routes of administration are preferred be-
cause they can enhance or facilitate drug ef-
fects. Different modes of administration have
advantages and disadvantages. The most
common routes of administration are:
 oral ingestion: probably the oldest and the
most common form of taking drugs. Ad-
vantages are convenience, no special
paraphernalia is required and degree of
safety for some drugs. Disadvantages are
the slow absorption of some substances
 chewing: used for coca leaf, tobacco,
betel-nut and tea. Absorption occurs
across the oral mucosa
 nasal insufflation: includes snuffing, na-
sal inhalation or snorting. Absorption is
through the nasal mucosa. Snuffing can
be used for cocaine, powdered opium,
heroin and tobacco. Sniffing of amyl nitrite
occurs, as does sniffing of petrol and other
volatile substances
 smoking: is used for a wide variety of sub-
stances including tobacco, cannabis,
opium, heroin, cocaine, amphetamines
and phencyclidine (PCP)
 rectal administration: commonly used in
medical treatment, it is also a method
sometimes used by drug users. Disadvan-
tages are the potential for irregular, unpre-
dictable and incomplete absorption
 parenterally (via injection): became pos-
sible in the late 19th century with the de-
velopment of the hypodermic needle. Ar-
guably this has irrevocably transformed
hedonistic drug use. Administration can
be intravenous (via a vein), intramuscu-
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lar (via a muscle), or subcutaneous (un-
der the skin). Each has advantages and
disadvantages. Injection carries with it a
range of important health risks including
transmission of viral and bacterial dis-
eases and tissue damage
Harm minimisation strategies provide oppor-
tunities to educate users about safer ways to
administer drugs. Safe injecting techniques
are especially important. Changing from one
route of administration to another may also
be a useful stepping stone to cutting down
and quitting.
Table 1–1 lists the major psychoactive drugs
and describes their intoxication effects and po-
tential adverse health effects.
For more information regarding specific effects
of particular drugs, including a discussion of
acute effects, high dose effects and effects of
chronic use, refer to the individual chapters in
Part 2 of this Handbook.
The website of the National Institute of Drug
Abuse (NIDA) located in the United States of
America contains additional useful information
about common names of drugs, routes of ad-
ministration and references for further reading.
Terminology
Throughout this Handbook, you will note
some variations in the language used to de-
scribe drug and alcohol use and associated
problems. In Australia, the preferred termi-
nology is ‘problematic use’ as this is less
pejorative than other terms. However, some
of the international and official classifications
include terms such as ‘abuse’ or ‘misuse’.
The preference is to avoid the use of nega-
tive or value-laden terms, labels or language.
As this Handbook is intended for a wide range
of health and human services workers terms
such as ‘patient’ and ‘client’ are used inter-
changeably.
DEFINITIONS OF DRUG AND
ALCOHOL PROBLEMS
Problematic drug use has been formally cat-
egorised in some systems as:
 hazardous use
 harmful use
 substance abuse
 substance dependence
Hazardous Use
Hazardous use refers to a pattern of sub-
stance use that increases the risk of harmful
consequences for the user. These conse-
quences can include physical and/or mental
health problems; some would also include
social consequences. Hazardous use refers
to patterns of use that are of public health sig-
nificance despite the absence of any current
disorder in the individual user.
Refer to National Institute on Alcohol Abuse and
Alcoholism (NIAAA) Thesaurus on their website.
Harmful Use
Harmful use (ICD–10) is defined as a pattern
of psychoactive substance use that is caus-
ing damage to health. The damage may be
physical (e.g. hepatitis following injection of
drugs) or mental (e.g. depressive episodes
www.nida.nih.gov
www.etoh.n iaaa.n ih .gov/
AODVol1/Aodthome.htm
See Chapters 3–12
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Table 1–1
Intoxication and potential adverse health effects
Intoxication effects Potential adverse health effects
Alcohol • reduced pain and anxiety
• feeling of wellbeing
• lowered inhibitions
• trauma and a range of effects on
cardiovascular, respiratory,
gastrointestinal, haematological
and neurological systems
• dependence
Opioids
• heroin
• codeine
• fentanyl
• morphine
• methadone
• buprenorphine
• pethidine
• pain relief
• euphoria
• drowsiness
• respiratory depression and arrest
• nausea
• confusion
• constipation
• sedation
• unconsciousness
• coma
• tolerance
• dependence
Stimulants
• amphetamines
• cocaine
• ecstasy/MDMA
• methyulphenidate
• nicotine
• caffeine
• increased heart rate,
blood pressure,
metabolism
• feelings of exhileration,
energy, increased mental
alertness
• rapid or irregular heartbeat
• reduced appetite
• weight loss
• heart failure
• dependence
Depressants
• barbiturates
• benzodiazepines
• reduced pain and anxiety
• feelings of wellbeing
• lowered inhibitions
• slowed pulse and
breathing
• lowered blood pressure
• poor concentration
• confusion
• fatigue
• impaired coordination, memory,
judgement
• respiratory depression and arrest
• dependence
Cannabinoids
• cannabis
• hash
• euphoria
• slowed thinking and
reaction time
• confusion
• impaired balance and
coordination
• cough
• frequent respiratory infections
• impaired memory and learning
• increased heart rate
• anxiety
• panic attacks
• tolerance
• dependence
Other – includes:
• hallucinogens such
as LSD; dissociative
anaesthetics
(ketamine, PCP);
inhalants (solvents,
nitrites and other
gases); steroids
• various effects • various effects
Source: adapted from the US National Institute of Drug Abuse (NIDA) website.
Information about alcohol has been added.
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Table 1–2
DSM–IV–TR (APA, 2000) Criteria for substance dependence
The maladaptive pattern of substance use, leading to clinically significant
impairment or distress, as manifested by three (or more) of the following,
occurring at any time in the same 12 month period.
1.
 
Tolerance, as defined by either a need for markedly increased amounts of
the substance to achieve intoxication or desired effect or a markedly
diminished effect with continued use of the same amount of the substance
2.
 
Withdrawal, as defined by either the characteristic withdrawal syndrome for
the substance or where the same (or a closely related) substance is taken to
relieve or avoid withdrawal symptoms
3.
 
The substance is often taken in larger amounts or over a longer period than
was intended
4.
 
There is a persistent desire or unsuccessful attempts to cut down or control
substance use
5.
 
A great deal of time is spent on activities necessary to obtain the substance
or to recover from its effects
6.
 
Social, occupational or recreational activities are given up or reduced
7.
 
Substance use is continued despite awareness of recurrent problems
associated with use
secondary to heavy alcohol intake). Harmful
use commonly, but not invariably, has adverse
social consequences. Social consequences,
however, in themselves, are not sufficient to
justify a diagnosis of harmful use.
Substance ‘Abuse’
Substance ‘abuse’ is a term used by DSM–
IV–TR (APA, 2000, p. 199). It is defined as a
maladaptive pattern of substance use lead-
ing to clinically significant impairment or dis-
tress, as manifested by one or more of the
following, occurring within a 12 month period:
 failure to fulfil major role obligations
 use in situations in which it is physically
hazardous
 recurrent substance-related legal problems
 continued use despite having persistent
or recurrent social or interpersonal prob-
lems caused or exacerbated by the effects
of the substance
Unlike dependence, ‘abuse’ is not character-
ised by withdrawal, tolerance or a pattern of
compulsive use, only the adverse conse-
quences of repeated use.
Substance Dependence
Substance dependence on the other hand, is
defined (APA, 2000) as a characteristic set of
cognitive, behavioural and physiological signs
in which the individual will continue to use the
substance despite considerable related prob-
lems. Tolerance has developed and withdrawal
symptoms are present upon cessation of the
drug. The actual criteria for dependence are
10
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summarised in Table 1–2 DSM–IV–TR (2000)
Criteria for Substance Dependence.
In addition to these criteria, the World Health
Organization (WHO) International Classifica-
tion of Diseases, 10th Edition (ICD–10) sug-
gests that another essential characteristic of
dependence is that the individual must pos-
sess a strong desire to take the substance
and is indeed consuming it (Proudfoot &
Teesson, 2000).
It is important to note that many problems as-
sociated with the use of alcohol or other
psychoactive drugs do not involve dependence.
That is, you do not need to be dependent on a
drug to experience harms from its use.
STANDARDS OF CARE
Attitudes Towards
Drug Users
Psychoactive drug users often experience dis-
crimination and stigma when accessing health
services. While not all health professionals
discriminate against drug users, poor treat-
ment and discriminatory practices have been
identified as primary barriers to accessing
health care.
Negative attitudes are often based on stere-
otypes and fears. Such stereotypes can result
in discrimination, stigma and marginalisation.
Like other groups in the community, drug us-
ers are a diverse group with differing needs
and backgrounds. In the health care context,
recognising the diverse needs of every indi-
vidual is critical to professional and effective
treatment and ensures appropriate standards
of care are met.
Drug Users’ Rights
Treating all illicit drug users as ‘drug seek-
ing’, unreliable and disruptive will not result
in a positive outcome for either the person
who uses drugs or the health professional.
Participation in an illegal behaviour does not
mean that individuals surrender their basic
health and human rights. Illicit drug users
should be treated in the same way as other
people, that is, as individuals with specific
needs requiring information and communi-
cation on all options, professional diagnosis
and where appropriate, treatment.
ROLE OF HEALTH AND HUMAN
SERVICES PROVIDERS
Medical Practitioners
and Nurses
Medical practitioners and nurses who are not
specialists in drug and alcohol have a criti-
cally important role to play in the provision of
drug and alcohol treatments.
General practitioners and other primary care
health professionals are particularly well
suited for this role because:
 85% of the population visit a general prac-
titioner at least once per year
 general practitioners and primary health
professionals are usually the first point of
contact with the health care system
 patients are often at a learning moment
and expect to receive lifestyle advice from
general practitioners
 general practitioners are in an ideal posi-
tion to link prevention with comprehensive,
continuing and holistic care
 general practitioners provide a range of
services that span the health care con-
tinuum from prevention of illness to treat-
ment and rehabilitation
(RACGP National Preventive & Community
Medicine Committee, 1998)
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Medical practitioners and nurses are ideally
placed to:
 provide relevant information about drugs
and alcohol to all patients
 identify drug- and alcohol-related problems
 provide interventions
 refer for specialist assessment and treat-
ment when required; and
 coordinate care and follow up patients over
time
There is a growing body of evidence about
the effectiveness of interventions and benefits
of treatment that medical practitioners and
nurses can provide. These include:
 screening
 assessment
 information and advice
 brief interventions for tobacco, alcohol and
to a lesser extent cannabis
 detoxification, including home detoxification
 pharmacotherapy for tobacco, alcohol and
opioid dependence
 counselling, including motivational inter-
viewing, and relapse prevention
 referral to clinicians with specialist skills
in drug and alcohol
 follow-up monitoring and care coordination
These interventions have been shown to be ef-
fective in specialist and non-specialist settings.
For clinicians with specific drug and alcohol com-
petencies, a more comprehensive role in the
care of patients can be undertaken including:
 management of intoxication and withdrawal
 motivational interviewing
 management of detoxification
 pharmacotherapy treatments
 counselling
 treatment of medical comorbidities
 management of psychiatric comorbidities
 care of pregnant women with drug- and
alcohol-related problems and their
neonates; and
 follow-up monitoring and review
Other Frontline Workers
The complexity and diversity of problems as-
sociated with alcohol and drug use has in-
creased substantially over the past decade.
The potential support and intervention roles
for health and human services workers has
increased accordingly. Evidence for the effi-
cacy of early intervention has been well es-
tablished and identifies an important role for
any professional in a position to intervene
for alcohol and drug problems.
Key professional groups identified as pivotal
frontline workers include:
 alcohol and other drug specialist workers
 general health workers such as medical
practitioners, nurses, Indigenous health
workers and psychologists
 volunteer workers in a variety of commu-
nity groups including parent and family
groups, self-help groups, church groups
and counselling support groups
 police and law enforcement personnel
 welfare professionals, including social
workers, youth workers and other commu-
nity-based workers
 teachers and education personnel
It is no longer assumed that support and in-
tervention for alcohol and other drug (AOD)
problems is the exclusive province of
specialist professionals. While interventions
and treatments have become more specific
and technical in recent years (most notably
in relation to pharmacological interventions)
there is also an expanded role for generalist
frontline workers especially from a prevention,
harm minimisation and early intervention
perspective.
12
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Health Professionals’ Role
with Aboriginal and
Torres Strait Islanders
There is a range of special considerations in
relation to the AOD use of Indigenous Aus-
tralians. Patterns and correlates of use are
often quite different and health care needs
more complex than for the wider community.
Proportionately fewer Indigenous people drink
than in the Australian community at large. How-
ever, amongst those who consume alcohol the
majority do so at hazardous and harmful levels,
often drinking heavily on a single occasion.
There is often intense social pressure for Indig-
enous drinkers to continue to drink. Relatedness
to others is deeply embedded within Aboriginal
social life and sharing alcohol (and increasingly
other drugs) naturally plays an important part in
this. Public pressure to share and socialise
around alcohol is very strong, and those who
try to moderate or give up may be criticised.
Health care workers can be valuable aids in sup-
porting moderate use or cessation.
Prevalence of tobacco smoking is 2 to 3 times
higher than the national average, and there
are very high rates of cannabis (yarndi, ganya)
use. It has also been recognised recently that
rates of injecting drug use amongst young In-
digenous people have grown exponentially
and are associated with very high levels of
diseases such as hepatitis C.  There are also
increasing levels of use of other drugs such
as heroin with high levels of needle sharing.
General practitioners and other health care
workers have considerable potential to help
motivate Indigenous patients to reconsider
their drinking and/or drug use. Health
professionals should not feel constrained
(e.g. by fears of being culturally inappropri-
ate), to provide a range of brief interventions
to patients just because they are Indigenous.
As is the case with any patient or client, such
advice should be offered sensitively and in
a non-judgmental manner, and avoid any
implication of criticism. Research into self-
quitting amongst Indigenous people
suggests that health care workers can be
more influential than they think (see Table
1–3).
The Australian Drug Information Network
(ADIN) contains useful links:
Health Professionals’ Role with
Culturally and Linguistically
Diverse (CALD) Groups
Cultural background and drug use
Australia is ethnically a highly diverse country.
A person’s cultural background i.e. country of
birth, language spoken at home, religion and
ethnic background may have an impact on drug
use and/or associated problems and their reso-
lution. Different cultures vary in their attitudes
to and use of alcohol and other drugs. Alcohol
consumption, for example, varies greatly within
and between countries. In Italy, for instance
wine is commonly consumed with meals but
intoxication is not accepted. Some cultures fa-
vour the use of drugs little known in Australia
(e.g. khat, betel nut), while alcohol is much less
widely used in many countries, including some
which are significant sources of refugees and
migrants to Australia. In many Asian countries,
the traditional use of opioids  once tended to
be by smoking.  However, this is rapidly chang-
ing with injecting becoming increasingly com-
mon among Asian populations.
Religious affiliation may also be relevant. Re-
ligious observance is often an important as-
pect of culture, and may play a part in the
manner and extent of drug use. A person of
Islamic background for instance may develop
a problem with alcohol, but be less willing to
discuss it and may fear community criticism.
www.adin.com.au/
indigenous.html
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Table 1–3
Why health care workers are influential amongst Indigenous people
Reason Explanation
Privacy of consultation Avoids the potential stigma of attending an identified
alcohol and other drug service, and provides the
necessary confidentiality.
Expectations of the
doctor’s role
Indigenous patients expect doctors and health care
workers to talk honestly about their health problems, to
diagnose and give advice. It is particularly important to
link the presenting problem with alcohol- or drug-related
problems where possible, as patient’s knowledge about
these links may be minimal. It is important to stress the
effect of the patient’s drinking and/or drug use on their
family responsibilities.
Respect for
specialised
knowledge
Medical practitioners in particular are known to have
specialised knowledge of the body. This invests them
with considerable authority amongst Indigenous people,
and provides doctors with significant potential to motivate
for change in drinking and other drug use behaviour.
Personalised advice
and providing
evidence of harm
Linking advice on alcohol consumption to the individual’s
presenting problem is more influential than a general talk
about alcohol awareness. Indigenous patients seem to
respond well to offers of biological tests, the results of
which provide objective proof of the harmful effects of
alcohol misuse. Such evidence can be particularly useful
to the indigenous patient.
Neutral advice from
an informed outsider
Professional advice on changing drinking behaviour can
motivate the individual to consider change, partly
because a doctor is usually an ‘outsider’, not of the
patient’s family or community. Community health workers
known to the patient can sometimes find it intrusive to
discuss alcohol- or drug-related matters with other
indigenous people. In the face of intense social pressures
to drink, authoritative advice from an outsider can be of
particular value. Having an external reason can legitimise
an individual’s refusal to participate in drinking sessions
with friends and family members, without causing
offence.
14
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The circumstances under which a person
came to Australia may also be important.
Those migrating under family reunion quo-
tas may have more support than refugees who
may have previously faced poverty, illness and
war. Some individuals may have depression
or post-traumatic stress disorder following
trauma or torture in their country of origin.
Prevention and
Treatment Strategies
Prevention and treatment programs need to
take into account the characteristics of individu-
als with Indigenous and non-English speaking
backgrounds. Different cultural values as well
as language issues need to be considered in
any prevention strategy. There is untapped
potential for ethnic newspapers and broadcast-
ing services to be used in primary prevention
strategies.
Secondary Prevention
Many screening tools have not been validated
with different ethnic or cultural groups and
should be used and interpreted with care. The
AUDIT alcohol screening tool has been vali-
dated with different cultural groups.
Interpreting and Translation
The use of skilled interpreters with the appro-
priate dialect and of the patient/client’s pre-
ferred gender is crucial. It is inappropriate to
use family members as interpreters. Even if the
patient does not see the need, an interpreter
may still be required to ensure an accurate
assessment and appropriate management
strategy.
Resources
NSW Drug and Alcohol Multicultural Educa-
tion Centre, DAMEC.
OTHER SPECIAL
NEEDS GROUPS
There are several other groups who have
special needs in relation to AOD use.  These
groups may not engage well in treatment un-
less their special needs are met.  These
groups include:
 those located in rural and remote areas
 women
 those of different sexual orientations
 youth
The last group, youth, are particularly impor-
tant to highlight.  More young people are en-
gaging in problematic AOD use at younger
ages.  They are especially vulnerable to AOD-
related problems due to age and inexperience.
Health and human services workers are in-
creasingly called upon to provide youth-
friendly and youth-appropriate services.
www.damec.org.au
See Chapter 3
Alcohol
‘The AUDIT’, p. 45
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HIS CHAPTER reviews key principles involved in identifica-
tion, management and intervention of alcohol and other
drug (AOD) problems. Issues covered here are expanded
on in relevant chapters.
Problems associated with the use of alcohol or other drugs can
be related to:
 intoxication
 regular use
 dependence
Not all problems are related to dependence or addiction.  Many
problems are related to non-dependent patterns of use that are
risky for either the person or those around them.  Interventions
should be tailored to the type of problems experienced or the na-
ture of the risks to which the individual is exposed.
HARM MINIMISATION
Harm minimisation is an important principle in the management
and intervention of AOD problems. Many intervention options are
pragmatic in nature and based on an understanding that changing
behaviour can be a lengthy, complex process. From a harm mini-
misation perspective abstinence may not be the highest or most
immediate priority: Emphasis is placed on reducing as many prob-
General Principles
of Management
and Intervention
T
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lems as possible associated with alcohol and
drug use, and not just focusing on the drug
use per se. Harm minimisation strategies ad-
dress the overall health and wellbeing of the
individual and the community at large.
EFFICACY OF TREATMENT
It is important to stress the efficacy of treat-
ments specific to problematic AOD use. In
contrast to common perceptions, there is a
range of effective, empirically evaluated
treatment options available. Treatment can
be successful. It is as successful as many
general medical treatments that are held in
high regard.
Intervention earlier rather than later is strongly
recommended. Treatment for long-term
chronic problems can also be very effective.
EARLY RECOGNITION
AND SCREENING
Early recognition is important as it can en-
able intervention to occur before dependence
or irreversible damage has developed. How-
ever, alcohol and drug problems can be diffi-
cult to detect, especially in the early stages.
Reasons include:
 not knowing what to look for
 lack of vigilance
 embarrassment about asking questions
 not knowing what to do if a problem is
uncovered
 the person’s denial or evasion
(Edwards, Marshall and Cook, 1997)
Detection rates can be improved by:
 routine enquiry about alcohol and drug use
 screening questionnaires
 biological screening (pathology tests)
 knowledge of common clinical presentations
ROUTINE ENQUIRY ABOUT
ALCOHOL AND DRUG USE
General practice and primary health care
offer a variety of opportunities to enquire
about alcohol and drug use; for example, in
the context of:
 new patients — as part of initial informa-
tion gathering
 management of chronic problems —
alcohol for example, is a risk factor in car-
diovascular disease, diabetes, depression
 management of acute problems, espe-
cially trauma, gastrointestinal disorders,
anxiety/stress, psychological problems
 preoperative assessment
 pre-conception and antenatal care
 enhanced Primary Care Medicare Benefit
Schedule items — health assessment,
care plans and case conferences
Screening Questionnaires
Use of general questionnaires covering life-
style issues such as smoking, diet, exercise,
alcohol and drug use may be less threaten-
Table 2–1
Treatment success for dependence
Drug of
Dependence
Success Rate
(%)
Alcohol 50 (40-70)
Opioids 60 (50-80)
Cocaine 55 (50-60)
Nicotine 30 (20-40)
Source: O’Brien and McLellan (1996)
Chapter 2
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ing and stigmatising for patients.
There is also a number of short, well vali-
dated questionnaires which can be used to
screen for alcohol problems. Screening and
brief interventions can readily be combined
in a single general practice consultation.
Biological Screening
A number of blood tests can be used to screen
for alcohol problems. However, they can be
less sensitive and specific than question-
naires. These screening tests include:
 full blood count, including MCV
 liver function tests, including gamma GT
 triglycerides
Urine testing can detect alcohol, other drugs
(e.g. cocaine, opioids cannabis,
benzodiazepines and barbiturates) and/or
their metabolites.
Screening tests for drug use include:
 full blood count, including white cell count
 liver function tests
 hepatitis B and C and HIV serology
COMMON CLINICAL
PRESENTATIONS
Indicators of alcohol- or drug-related problems
are wide-ranging and can involve:
 cardiovascular
 gastrointestinal
 musculoskeletal
 neurological
 dermatological
 genito-urinary systems
 accidents/trauma, social and legal incidents
Indicators of problematic drug use can in-
clude:
 infections (injecting users)
 accidents/trauma
 psychiatric problems
 behavioural, social and legal incidents
Assessment
Assessment is critical and has several purposes:
 to identify substance use behaviour early
 to discover the extent of use and its health
effects
 to examine the social context of sub-
stance use in both the patient and sig-
nificant others
 to determine a care plan and appropriate
interventions
(Rassool, 1998)
The assessment phase should fulfil four im-
portant functions:
1. developing a therapeutic relationship
based on trust, empathy and a non-judg-
mental attitude
2. helping the client to accurately reappraise
their drug use, which may in turn facilitate
the desire to change
3. facilitating a review of the client’s past and
present circumstances and linking these
to current drug use
4. encouraging the client to reflect on the
See Chapter 13
Psychosocial Interventions
See Chapters 3–12 for more
detail about individual drugs
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choices and consequences of drug using
behaviour
(Helfgott, 1997)
Traditionally treatment success was meas-
ured by abstinence. Today there is more
emphasis on the client’s:
 wellbeing
 beliefs about drinking and drug use
 readiness to change
 alcohol- and drug-related expectancies
 social functioning and social support
These are all important predictors of success.
Current approaches to treatment of alcohol-
and drug-related problems reflect a continuum
of treatment.
MANAGEMENT OF
LOW LEVEL PROBLEMS
Low level drug and alcohol problems are much
more common than dependence and are
major causes of morbidity and mortality. Indi-
viduals with low level problems are better
suited to brief and early interventions whereas
individuals experiencing more severe prob-
lems need more specialised treatment (Na-
tional Expert Advisory Committee on Alcohol,
2001).
A ‘brief intervention’ is considered to be:
‘any intervention that involves a minimum
of professional time in an attempt to
change drug use… Any intervention re-
quiring a total of between five minutes and
two hours’
(Heather, 1990)
Brief interventions are particularly suitable for
primary care but can also be used in emergency
departments, hospital wards or outpatient clin-
ics and a range of non-medical settings.
They are recommended for individuals with:
 hazardous/harmful alcohol use without
dependence
 a low to moderate dependence on alcohol
 a dependence on nicotine
 a low to moderate dependence on cannabis
(Best Practice in Alcohol and Other Drug In-
terventions Working Group, 2000).
There is compelling evidence for the effec-
tiveness of brief interventions to reduce haz-
ardous and harmful alcohol consumption by
30–40% (WHO Brief Intervention Study
Group, 1996).
Brief interventions are not considered suitable
for:
 more complex patients with additional psy-
chological/psychiatric issues
 patients with severe dependence
 patients with poor literacy skills
 patients with difficulties related to cogni-
tive impairment
In these instances, more in-depth interven-
tion is recommended (Heather, 1995).
Brief intervention can take a variety of forms
but often includes:
 brief assessment
 self-help materials
 information on safe levels of consumption
 advice on reducing consumption
 harm reduction
 relapse prevention
 assessment of readiness to change, in-
Chapter 2
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cluding motivational interviewing
 brief counselling, including problem solv-
ing and goal setting
 follow-up
Six therapeutic elements are common to suc-
cessful brief interventions (FRAMES):
F. Feedback — provide feedback from your
clinical assessment
R. Responsibility — emphasise the person’s
personal responsibility for their drug use
and associated behaviour
A. Advice — provide clear, practical advice
and self-help material
M. Menu — offer a range of behaviour change
and intervention options
E. Empathy — express non-judgmental em-
pathy and support
S. Self-efficiency — stress belief in the per-
son’s capacity for change
(Miller and Sanchez, 1993)
Psychosocial Interventions
Psychological interventions are a key com-
ponent of a comprehensive treatment program
and can involve group therapy or individual
counselling.
‘…counselling alone is not usually suffi-
cient to change the drug taking behav-
iour of most clients’
(Jarvis et al., 1995)
Counselling is a joint approach between the
counsellor and the client with treatment plans
negotiated and agreed upon by both parties.
No single psychological approach is supe-
rior, and the treatment program should be tai-
lored to the individual patient/client, taking
into consideration such factors as culture,
age, gender and presence of comorbidity.
General counselling should include:
 linking patients with the appropriate serv-
ices while the patient is still engaged
 anticipating and developing strategies
with the patient to cope with difficulties
before they arise
 specific evidence-based interventions
where appropriate (e.g. goal setting, cog-
nitive behavioural therapy, motivational
enhancement therapy, problem solving)
 focusing on positive internal and external
resources and successes as well as prob-
lems and disabilities
 consideration of the wider picture and
helping the patient on a practical level
(e.g. with food, finances, housing)
 where appropriate, involving key support-
ive others to improve the possibility of be-
havioural change outside the therapeutic
environment
(Best Practice in Alcohol and Other Drug In-
terventions Working Group, 2000)
Mutual aid groups such as Alcoholics Anony-
mous, Narcotics Anonymous, Al-Anon (for
relatives of alcohol dependent individuals) and
Alateen (for adolescent relatives) are also
available.  Their approaches are based on the
12 Steps, a set of principles that emphasise
personal responsibility and honesty.
MAINTENANCE
PHARMACOTHERAPIES
A number of effective therapeutic drugs are
now available for the treatment of dependence,
primarily for alcohol, nicotine and opioid de-
See Chapter 13
Psychosocial Interventions
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pendence.  It is likely that the use of pharma-
cotherapies will increase in the future.
Pharmacotherapies should not be considered
as stand alone treatments but should be used
as part of a comprehensive treatment pro-
gram, including supportive counselling, other
relevant therapies and social support.
PHARMACOTHERAPIES FOR
ALCOHOL DEPENDENCE
Acamprosate (Campral®)
This is an anticraving agent which acts as a
GABA-receptor agonist. Randomised control-
led trials have shown:
 reduced quantity and frequency of drink-
ing in patients who do not achieve com-
plete abstinence
 reduced rates of relapse (where relapse
is defined as consumption of any alcohol)
 increased percentages of abstinent days
during treatment
 increased rates of abstinence
Naltrexone (Revia®)
This anticraving agent is a competitive
opioid antagonist which blocks the euphoric
and reinforcing effects of alcohol.
Randomised controlled trials have shown:
 reductions in the amount and frequency
of drinking overall
 reductions in the rate and relapse into
heavy drinking (where relapse is defined
as a return to > 5 drinks per day)
 increased rates of alcohol abstinence
Both naltrexone and acamprosate are avail-
able on the Pharmaceutical Benefits Scheme
(PBS) for use within a comprehensive treat-
ment program.
Disulfiram (Antabuse®)
An alcohol-sensitising agent which inhibits
aldehyde dehydrogenase causing a toxic
build-up of acetaldehyde if alcohol is con-
sumed. This results in unpleasant symptoms
such as facial flushing, nausea, vomiting,
sweating and palpitations.
Randomised controlled trials have shown
variable results and only a modest effect in
promoting abstinence. Disulfiram is not avail-
able on the PBS.
PHARMACOTHERAPIES
FOR OPIOID DEPENDENCE
Buprenorphine
A strong opioid analgesic with both partial
agonist and partial antagonist properties. It is
an alternative to methadone for withdrawal
and maintenance treatment, and has a much
lower risk of death from overdose than metha-
done. Buprenorphine is listed on the PBS as
S100 under Section 100 of the National Health
Act 1953 and is approved by the Therapeutic
Goods Administration (TGA).
Methadone
This is a long-acting synthetic opioid which
can be used for both withdrawal and mainte-
nance treatment. It decreases the need for
heroin-dependent individuals to regularly use
intravenous opioids. Methadone mainte-
nance programs monitor drug use and should
provide ongoing counselling and support.
Methadone is listed on the PBS as S100
under Section 100 of the National Health Act
1953 and is approved by the Therapeutic
Goods Administration (TGA).
Chapter 2
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Levoalphaacetylmethadol
(LAAM)
LAAM is a synthetic opioid analgesic which
acts similarly to methadone. It is long-acting
and only needs to be taken three times per
week. Overseas trials suggest that LAAM is
as safe as methadone and has similar treat-
ment outcomes and patient retention. This
drug is not available for use in Australia.
Naltrexone (Revia®)
This is a competitive opioid antagonist, which
completely blocks the effects of opioids for
24 to 72 hours. Maintenance therapy is suit-
able for highly motivated patients who wish
to remain abstinent, are socially and psycho-
logically stable and have good social sup-
port. Naltrexone is not listed on the PBS for
opioid dependence but is approved by the
TGA as an adjunctive therapy. Clinical trials
are also underway using naltrexone for rapid
detoxification.
WITHDRAWAL AND
DETOXIFICATION
Detoxification is withdrawal from a drug in a
supervised way in order to minimise withdrawal
symptoms and risks related to withdrawal.
Details of withdrawal management are cov-
ered in the management and intervention sec-
tions of relevant chapters on specific drugs.
Effective withdrawal management may be
performed in the home supported by the GP,
other health workers and non-using supportive
relatives or friends. This form of withdrawal
management depends on:
 the drug of dependence
 the severity of the dependency
 the wishes of the patient
Home-based withdrawal management
should be considered:
 when there is no evidence of severe with-
drawal, e.g. tremor, hallucinations, disori-
entation*
 where there is no past history of delirium
tremens or of fits*
 in the presence of supportive relatives who
elect to stay with the patient during the
period of detoxification
 when there is no evidence of a medical
illness such as pneumonia or pancreati-
tis*
 when no previous history or evidence of
suicide is contemplated
 where the patient does not have access
to the drug from which they are being with-
drawn
(* in the case of alcohol)
Withdrawal can be medicated (assisted by the
use of controlled sedatives) or non-medicated.
The latter is appropriate for patients who have
no co-existing medical disorders and when
only a mild withdrawal can be anticipated.
In cases of multiple drug use, patients may not
wish to withdraw from all substances at the
same time. Withdrawal management should be
part of an ongoing treatment program linked to
coping and relapse prevention strategies.
INTOXICATION
AND OVERDOSE
Intoxication is defined as the intake of a
quantity of a substance which exceeds the
individual’s tolerance.
Further reading:
Ellenhorn & Barceloux (1988)
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Overdose is defined as the state that occurs
when a person has ingested a quantity of a
drug that exceeds tolerance and produces
behavioural and physical abnormalities.
Details of intoxication and overdose manage-
ment are covered under the management and
intervention sections in each Chapter.
When presented with an intoxicated or over-
dose patient the priority is ABC First Aid pro-
cedures:
A — Airway
B — Breathing
C — Circulation/cardiac
In acute overdose it is recommended that pa-
tients are closely observed, monitored and re-
ferred to an acute hospital.
Do not assume that alcohol or drugs are the
sole cause of the patient’s coma. Other possi-
ble causes include:
 trauma
 epilepsy
 metabolic abnormalities – diabetes, he-
patic failure, hypercalcaemia, renal fail-
ure
 cerebrovascular events – cerebral haem-
orrhage/thrombosis, abscess, tumour
 cardiovascular events – arrhythmias,
myocardial infarction
 respiratory failure
 infection – meningitis, encephalitis
Once intoxication or overdose has been
treated it is important to:
 ask about depression, suicidal ideation
(may need a referral to a psychiatrist)
 explore withdrawal management and
treatment options
COEXISTING MENTAL
HEALTH PROBLEMS
In patients using alcohol and other drugs co-
existing mental health problems, such as anxi-
ety and depression, are not uncommon.  It is
important to distinguish symptoms which are:
 part of a primary psychiatric disorder
 secondary to problems such as marital
conflict, homelessness or legal problems
 drug or alcohol induced
DRUG SEEKING
Clinical Features
Patients seeking prescribed drugs for non-
medical use often approach emergency depart-
ments of major hospitals or general practition-
ers’ surgeries at busy times or shortly before
closing. Patients may choose a general prac-
titioner who does not know them or who are
known to prescribe drugs very readily.
Drug seeking patients are usually:
 polydrug using
 males
 aged in their twenties or thirties
The drugs sought are usually:
 opioid analgesics; or
 benzodiazepines
The presentations for analgesics usually in-
volve painful conditions where there are few
physical signs, such as headache, renal colic
See Chapter 18
Coexisting Mental Illness
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or backache. The names of analgesics which
have proved effective on previous occasions
are often referred to with familiarity.
The most frequently requested opioid is
pethidine by injection.
Commonly, patients will claim that analge-
sics other than the preferred type:
 have previously proved ineffective and/or
 resulted in severe side effects including
an allergic reaction.
A careful history plus physical examination
contributes substantially to the diagnosis and
management plan. Suspicion of illicit drug use
is supported by a history of common compli-
cations of drug use (such as hepatitis C, en-
docarditis or previous incarceration). Physical
examination should include inspection for
track marks. It is often helpful to have a pa-
tient discretely observed by an experienced
nurse for signs of variability in the severity of
signs of pain.
Management
As special tests usually cannot prove if the
patient’s symptoms result from organic dis-
ease, the final clinical decision depends on
the doctor’s judgment and experience. In most
cases, decisions are relatively easy. When
uncertain, the choice has to be made between
possibly withholding analgesia from a patient
in severe pain or possibly prescribing an opioid
analgesic to a malingering patient. The former
is a far more serious error.
Injections of ketorolac (Toradol®), a non-
steroidal anti-inflammatory drug (NSAID), is
a safe way of providing a potent analgesic
without prescribing an opioid.
Buprenorphine is a potent analgesic which
provides minimal euphoria but this can pre-
cipitate opioid withdrawal if the patient has
withheld a history of recent opioid use.
Presentations for benzodiazepines often in-
volve a history of anxiety or insomnia due to
a recent bereavement. Short-acting
benzodiazepines should only be prescribed
in very special circumstances and then only
in small quantities. If benzodiazepines have
to be prescribed, it is better to select long-
acting forms but in small quantities.
Doctors who consider that a patient is seek-
ing drugs should gently advise the patient that
they are concerned about this possibility and
offer relevant assistance or referral.
GENERAL MANAGEMENT
APPROACHES
Support and treatment for drug users should
follow the general supportive and common-
sense approaches described below.
Clinicians should:
 not judge the user and should not insist
on abstinence
 seek to engage and retain the user in treat-
ment for as long as possible, as retention
is associated with better outcomes
(Simpson et al., 1999)
 ensure understanding of the client/pa-
tient’s treatment goals:
 to make it through an acute crisis?
 to reduce frequency and/or quantity of
drug use?
 to achieve long-term abstinence?
 tailor the treatment where possible to
meet those goals, including referral when
appropriate to:
 treatment programs
 individual counsellors
 family counsellors
 self-help groups such as NA
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 remember the need for flexibility of serv-
ice delivery; as goals and outcomes
change throughout the course of treat-
ment, the treatment program should be
adjusted to reflect these changes
 provide as multifaceted and intensive a
program as possible, as more intensive
psychosocial treatment programs are as-
sociated with better outcomes (Crits-
Cristoph, 1999).
Readiness to Change
In patients who do not wish to become absti-
nent despite significant impairment related to
drug use, the clinician should attempt to:
 establish an empathetic, respectful rela-
tionship
 retain contact with the client
 maximise physical and mental health, as
clients will find it difficult to achieve long-
term abstinence if chronic medical prob-
lems have not been adequately treated
 enhance motivation toward abstinence by
educating clients and their significant oth-
ers about the usual course of drug depend-
ence and the relationship between drug
use and current and/or future problems
 emphasise the client’s responsibility for
their own actions
 help clients rebuild a life without drugs
through:
 vocational counselling
 family counselling
 helping them build a network of non-
drug using peers
 showing them how to use free time
appropriately
Chapter 2
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RESOURCES
Further reading: A basic modern text on toxicology is Ellenhorn, M. & Barceloux, D.G. (1988),
Medical Toxicology: Diagnosis and Treatment of Human Poisonings, Elsevier, New York.
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